• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012-2018 Product Image

Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012-2018

  • ID: 2622800
  • July 2013
  • Region: Global
  • 92 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Covidien plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis International AG
  • MORE

'Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018'

The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics.

The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 – 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering READ MORE >

FEATURED COMPANIES

  • Abbott Laboratories
  • Covidien plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis International AG
  • MORE

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Pain Management – Types of Treatments
3.2 World Health Organization's “Pain Ladder” for cancer
3.3 Market Trends and Future Outlook
3.3.1 Impact of generics
3.3.2 Key patent expirations
3.4 Market Drivers
3.4.1 Global increasing incidence of chronic pain disorders
3.4.2 Favorable regulatory scenario and healthcare reforms
3.4.3 Easy and effective medications
3.4.4 Impact analysis of market drivers
3.5 Market Restraints
3.5.1 Prescription drug abuse
3.5.2 Pain advocacy groups losing power, influence and funding
3.5.3 Adulteration and fake drugs thrive in developing regions
3.5.4 Long term pain relief from surgical procedures, alternative therapies and medical devices
3.5.5 Impact analysis of market restraints
3.6 Market Opportunities
3.6.1 Novel molecule combinations and drug delivery techniques are expected to become a rising opportunity in forecast period
3.6.2 Generics expected to be a rising opportunity globally
3.7 Porter's Five Forces Analysis
3.7.1 Bargaining power of buyers
3.7.2 Bargaining power of suppliers
3.7.3 Threat of substitutes
3.7.4 Threat of new entrants
3.7.5 Competitive rivalry
3.8 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 Global Pain Management Therapeutics Market, by Therapeutic Class
4.1 Anticonvulsants
4.1.1 Current and future market scenario
4.2 Antidepressants
4.2.1 Current market scenario and patent expiry effect
4.2.2 Future market scenario
4.3 Anesthetics
4.3.1 Current market scenario and patent expiry effect
4.3.2 Pipeline drugs and their effect
4.3.3 General Anesthetics
4.3.4 Local Anesthetics
4.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.4.1 Current market scenario and patent expiry effect
4.5 Opioids
4.5.1 Current market scenario and patent expiry effect
4.5.2 Pipeline drugs and their effect on the market
4.5.2.1 MoxDuo IR
4.5.2.2 Remoxy
4.6 Anti-Migraine Agents
4.6.1 Pipeline drugs and additional approvals
4.7 Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 Global Pain Management Therapeutics Market, by Indication
5.1 Neuropathic Pain
5.2 Fibromyalgia
5.3 Arthritic Pain
5.3.1 Osteoarthritis (OA)
5.3.2 Rheumatoid Arthritis (RA)
5.4 Chronic Back Pain
5.5 Migraine
5.6 Post-operative pain
5.7 Cancer Pain

Chapter 6 Global Pain Management Therapeutics Market, by Geography
6.1 Overview
6.1.1 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)
6.1.2 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
6.2 North America
6.2.1 North America Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.3 Europe
6.3.1 Europe Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and
Forecast, 2010 - 2018 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Pain Management Therapeutics Market (2011)
7.1.1 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
7.1.2 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
7.2 Pipeline Snapshot: Pain Management Therapeutics
7.2.1 MoxDuo (morphine and oxycodone)
7.2.2 Remoxy (oxycodone)
7.2.3 Posidur (SABER-bupivacaine)
7.2.4 Zecuity (transdermal sumatriptan)

Chapter 8 Recommendations
8.1 Development of novel combination formulations
8.2 Addressing unmet needs: drug abuse and side-effects
8.3 Generics manufacturers: Investment in emerging markets such as India, China and Russia
8.4 Mergers and acquisitions to enter or strengthen market presence

Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.1.5 Recent Developments
9.2 Allergan, Inc.
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.2.5 Recent Developments
9.3 Covidien plc
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.5 Recent Developments
9.4 Durect Corporation
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Pipeline Products
9.4.4 Business Strategies
9.4.5 Recent Developments
9.5 Eli Lilly and Company
9.5.1 Business Overview
9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.5.5 Recent Developments
9.6 Endo Health Solutions, Inc.
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.6.5 Recent Developments
9.7 Forest Laboratories, Inc.
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.7.5 Recent Developments
9.8 GlaxoSmithKline plc
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.8.5 Recent Developments
9.9 Hospira, Inc.
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.9.5 Recent Developments
9.10 Johnson & Johnson
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.10.5 Recent Developments
9.11 Merck & Co., Inc.
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.11.5 Recent Developments
9.12 Mundipharma International Ltd.
9.12.1 Company Overview
9.12.2 Financial Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.12.5 Recent Developments
9.13 Novartis International AG
9.13.1 Company Overview
9.13.2 Financial Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.13.5 Recent Developments
9.14 NuPathe, Inc.
9.14.1 Company Overview
9.14.2 Financial Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.14.5 Recent Developments
9.15 Pain Therapeutics, Inc.
9.15.1 Company Overview
9.15.2 Financial Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.15.5 Recent Developments
9.16 Pfizer, Inc.
9.16.1 Company Overview
9.16.2 Financial Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.16.5 Recent Developments
9.17 Purdue Pharma L.P.
9.17.1 Company Overview
9.17.2 Financial Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.17.5 Recent Developments
9.18 QRx Pharma Ltd.
9.18.1 Company Overview
9.18.2 Financial Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.18.5 Recent Developments
9.19 Sanofi
9.19.1 Company Overview
9.19.2 Financial Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
9.19.5 Recent Developments
9.20 Teva Pharmaceutical Industries Limited
9.20.1 Company Overview
9.20.2 Financial Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies
9.20.5 Recent Developments
9.21 UCB (Union Chemnique Belge) S.A.
9.21.1 Company Overview
9.21.2 Financial Overview
9.21.3 Product Portfolio
9.21.4 Business Strategies
9.21.5 Recent Developments

List of Figures

FIG. 1 Pain Management Therapeutics Market Segmentation
FIG. 2 Global Pain Management Therapeutics Market, by Therapeutic Class, 2011 (USD Million)
FIG. 3 Global Pain Management Therapeutics Market, by Indication, 2011 (USD Million)
FIG. 4 Porter's Five Forces Analysis: Global Pain Management Therapeutics Market
FIG. 5 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)
FIG. 6 Global Anticonvulsants Market for Pain Management, 2010 – 2018 (USD Million)
FIG. 7 Global Antidepressants Market for Pain Management, 2010 – 2018 (USD Million)
FIG. 8 Global Antidepressants Market for Pain Management, 2010 – 2015 (USD Million)
FIG. 9 Global Antidepressants Market for Pain Management, 2015 – 2018 (USD Million)
FIG. 10 Global Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 11 Global Anesthetics Market, 2010 – 2015 (USD Million)
FIG. 12 Global Anesthetics Market, 2015 – 2018 (USD Million)
FIG. 13 Global General Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 14 Global Local Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 15 Global Non-Steroidal Anti-Inflammatory Drugs Market, 2010 – 2018 (USD Million)
FIG. 16 Global Opioids Market, 2010 – 2018 (USD Million)
FIG. 17 Global Opioids Market, 2010 – 2015 (USD Million)
FIG. 18 Global Opioids Market, 2015 – 2018 (USD Million)
FIG. 19 Global Anti-Migraine Agents Market, 2010 – 2018 (USD Million)
FIG. 20 Global Anti-Migraine Agents Market, 2015 – 2018 (USD Million)
FIG. 21 Global Other Non-Narcotic Analgesics Market, 2010 – 2018 (USD Million)
FIG. 22 Global Neuropathic Pain Market, 2010 – 2018 (USD Million)
FIG. 23 Global Fibromyalgia Market, 2010 – 2018 (USD Million)
FIG. 24 Global Arthritic Pain Market, 2010 – 2018 (USD Million)
FIG. 25 Global Chronic Back Pain Market, 2010 – 2018 (USD Million)
FIG. 26 Global Migraine Market, 2010 – 2018 (USD Million)
FIG. 27 Global Post-operative Pain Market, 2010 – 2018 (USD Million)
FIG. 28 Global Cancer Pain Market, 2010 – 2018 (USD Million)
FIG. 29 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
FIG. 30 North America Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 31 Europe Pain Management Market, 2010 – 2018 (USD Million)
FIG. 32 Asia-Pacific Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 33 RoW Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 34 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
FIG. 35 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
FIG. 36 Posidur Vs Others: A Comparison of Pain Relief Duration
FIG. 37 Annual Revenues: Abbott Laboratories, 2010 – 2012 (USD million)
FIG. 38 Annual Revenues: Allergan, Inc., 2010 - 2012 (USD million)
FIG. 39 Annual Revenues: Covidien plc, 2010 – 2012 (USD million)
FIG. 40 Annual Revenues: Durect Corporation., 2010 -2012 (USD million)
FIG. 41 Annual Revenues: Eli Lilly and Company, 2010 – 2012 (USD million)
FIG. 42 Annual Revenues: Endo Health Solutions, Inc., 2010 – 2012 (USD million)
FIG. 43 Annual Revenues: Forest Laboratories, Inc., 2010 – 2012 (USD million)
FIG. 44 Annual Revenues: GlaxoSmithKline plc, 2010 – 2012 (USD million)
FIG. 45 Annual Revenues: Hospira, Inc., 2010 – 2012 (USD million)
FIG. 46 Annual Revenues: Johnson & Johnson, 2010 – 2012 (USD million)
FIG. 47 Annual Sales: Merck & Co., 2010 – 2012 (USD million)
FIG. 48 Annual Revenues: Novartis international AG , 2010 – 2012 (USD million)
FIG. 49 Annual Revenues: Pain Therapeutics, Inc., 2010 - 2012 (USD million)
FIG. 50 Annual Revenues: Pfizer, Inc., 2010 – 2012 (USD million)
FIG. 51 Annual Revenues: QRx Pharma Ltd., 2010 - 2012 (USD million)
FIG. 52 Annual Sales: Sanofi, 2010 – 2012 (USD million)
FIG. 53 Annual Revenues: Teva Pharmaceutical Industries Limited, 2010 – 2012 (USD million)
FIG. 54 Annual Revenues: UCB, S.A., 2010 – 2012 (USD million)

List of Tables

TABLE 1 Market Snapshot: Global Pain Management Therapeutics Market
TABLE 2 Impact Analysis of Market Drivers
TABLE 3 Impact Analysis of Market Restraints
TABLE 4 Global Anesthetics Market, by Segments, 2010 – 2018 (USD Million)
TABLE 5 Licensed Pharmaceuticals for Neuropathic Pain Management
TABLE 6 Key Licensed Pharmaceuticals for Arthritic Pain Management
TABLE 7 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)
TABLE 8 North America Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 9 Europe Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 10 Asia-Pacific Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 11 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

- Abbott Laboratories
- Allergan, Inc
- Covidien plc
- Durect Corporation
- Eli Lilly and Company
- Endo Health Solutions, Inc
- Forest Laboratories, Inc
- GlaxoSmithKline plc
- Hospira, Inc
- Johnson & Johnson
- Merck & Co, Inc
- Mundipharma International Ltd
- Novartis International AG
- NuPathe, Inc
- Pain Therapeutics, Inc
- Pfizer, Inc
- Purdue Pharma LP
- QRx Pharma Ltd
- Sanofi
- Teva Pharmaceutical Industries Limited
- UCB (Union Chemnique Belge) SA

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos